Blood particle test may predict liver failure and cancer risk

NCT ID NCT07185360

Not yet recruiting Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at tiny particles in the blood, called extracellular vesicles, to see if they can predict serious liver problems like liver failure or liver cancer. Researchers will collect blood samples from 845 people, including healthy volunteers, diabetes patients, and those with liver disease, and track their health over time. The goal is to develop simple tests that help doctors decide who needs closer monitoring or early treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to simple blood tests that predict liver disease worsening or liver cancer, helping doctors monitor patients more effectively.
What could go wrong: This is an observational study, not a treatment trial. The tests may not prove accurate enough for routine use, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis fibrotic liver disease Hepatic Insufficiency hepatocellular carcinoma liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASES

Contacts and locations

Locations

Bichat Hospital, Beaujon Hospital, Cochin Hospital and Lariboisière Hospital

Paris, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.